Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06248619 · ClinicalTrials.gov registry record · Phase 3
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
A Phase 3 study of Thyroid Eye Disease, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
- 20
- Study locations
NCT06248619 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Amgen. The registered enrollment target is 89 participants, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 20 states.
The verdict
NCT06248619, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Teprotumumab
Study Locations (20)
Arizona
- Catalina Eye Care - NVISION - PPDS - Tucson
Illinois
- Advanced Quality Medical Research - Orland Park
Michigan
- W Kellogg Eye Center - Ann Arbor
Nevada
- Las Vegas Endocrinology - Henderson
New Jersey
- The Center for Eye and Facial Plastic Surgery - Somerset
Oregon
- Casey Eye Institute -515 SW Campus Dr - Portland
Pennsylvania
- Scheie Eye Institute - Philadelphia
Tennessee
- University of Tennessee Health Science Center - 848 Adams Ave - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2026-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06248619
The ClinicalTrials.gov registry entry for NCT06248619 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (12% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06248619 reports 20 study locations spanning 20 distinct geographic areas - top geographies include Arizona, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT06248619 about?
NCT06248619 is a clinical study titled "A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease". The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
What is the current status of trial NCT06248619?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2024-07-05. Estimated completion is 2026-09-02.
What conditions does trial NCT06248619 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06248619?
The interventions under investigation include: Placebo (OTHER), Teprotumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06248619?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06248619 being conducted?
This trial has 20 study locations across Arizona, Illinois, Michigan, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.